{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:51:44Z","timestamp":1792270304160,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11897-024-00659-9","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T03:41:11Z","timestamp":1712634071000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Combinational Diuretics in Heart\n            Failure"],"prefix":"10.1007","volume":"21","author":[{"given":"Joan Carles","family":"Trull\u00e0s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cobo-Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Formiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Lu\u00eds","family":"Morales-Rull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"659_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","volume":"22","author":"A Groenewegen","year":"2020","unstructured":"Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of\n                        heart failure. Eur J Heart Fail. 2020;22:1342\u201356. https:\/\/doi.org\/10.1002\/ejhf.1858.","journal-title":"Eur J Heart Fail"},{"key":"659_CR2","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jacbts.2021.10.018","volume":"7","author":"A Sharma","year":"2022","unstructured":"Sharma A, Verma S, Bhatt DL, Connelly KA, Swiggum E,\n                        Vaduganathan M, Zieroth S, Butler J. Optimizing foundational therapies in\n                        patients with HFrEF: how do we translate these findings into clinical care?\n                        JACC Basic Transl Sci. 2022;7:504\u201317. https:\/\/doi.org\/10.1016\/j.jacbts.2021.10.018.","journal-title":"JACC Basic Transl Sci"},{"key":"659_CR3","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M,\n                        et al. Focused update of the 2021 ESC Guidelines for the diagnosis and\n                        treatment of acute and chronic heart failure. Eur Heart J. 2023;ehad195. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","DOI":"10.1093\/eurheartj\/ehad195"},{"key":"659_CR4","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/ejhf.890","volume":"19","author":"O Chioncel","year":"2017","unstructured":"Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF,\n                        Crespo-Leiro MG, et al. Clinical phenotypes and outcome of patients\n                        hospitalized for acute heart failure: the ESC Heart Failure Long-Term\n                        Registry. Eur J Heart Fail. 2017;19:1242\u201354. https:\/\/doi.org\/10.1002\/ejhf.890.","journal-title":"Eur J Heart Fail"},{"key":"659_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca\n                        HP, Martens P, et al. The use of diuretics in heart failure with congestion\n                        - a position statement from the Heart Failure Association of the European\n                        Society of Cardiology. Eur J Heart Fail. 2019;21:137\u201355. https:\/\/doi.org\/10.1002\/ejhf.1369.","journal-title":"Eur J Heart Fail"},{"key":"659_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s11739-018-02019-7","volume":"14","author":"JC Trull\u00e0s","year":"2019","unstructured":"Trull\u00e0s JC, Casado J, Morales-Rull JL, Formiga F, Conde-Martel\n                        A, Quir\u00f3s R, et al. Prevalence and outcome of diuretic resistance in heart\n                        failure. Intern Emerg Med. 2019;14:529\u201337. https:\/\/doi.org\/10.1007\/s11739-018-02019-7.","journal-title":"Intern Emerg Med"},{"key":"659_CR7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/ehf2.13696","volume":"9","author":"Z Bl\u00e1zquez-Bermejo","year":"2022","unstructured":"Bl\u00e1zquez-Bermejo Z, Farr\u00e9 N, Caravaca Perez P, Llagostera M,\n                        Mor\u00e1n-Fern\u00e1ndez L, Fort A, et al. Dose of furosemide before admission\n                        predicts diuretic efficiency and long-term prognosis in acute heart failure.\n                        ESC Heart Fail. 2022;9:656\u201366. https:\/\/doi.org\/10.1002\/ehf2.13696.","journal-title":"ESC Heart Fail"},{"key":"659_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrcardio.2014.215","volume":"12","author":"JM ter Maaten","year":"2015","unstructured":"ter Maaten JM, Valente MA, Damman K, Hillege HL, Navis G, Voors\n                        AA. Diuretic response in acute heart failure-pathophysiology, evaluation,\n                        and therapy. Nat Rev Cardiol. 2015;12:184\u201392. https:\/\/doi.org\/10.1038\/nrcardio.2014.215.","journal-title":"Nat Rev Cardiol"},{"key":"659_CR9","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","volume":"75","author":"GM Felker","year":"2020","unstructured":"Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic\n                        therapy for patients with heart failure: JACC state-of-the-art review. J Am\n                        Coll Cardiol. 2020;75:1178\u201395. https:\/\/doi.org\/10.1016\/j.jacc.2019.12.059.","journal-title":"J Am Coll Cardiol"},{"issue":"6 Pt 2","key":"659_CR10","doi-asserted-by":"publisher","first-page":"F1256","DOI":"10.1152\/ajprenal.1988.255.6.F1256","volume":"255","author":"B Kaissling","year":"1988","unstructured":"Kaissling B, Stanton BA. Adaptation of distal tubule and\n                        collecting duct to increased sodium delivery. I Ultrastruct Am J Physiol.\n                        1988;255(6 Pt 2):F1256\u201368. https:\/\/doi.org\/10.1152\/ajprenal.1988.255.6.F1256.","journal-title":"I Ultrastruct Am J Physiol"},{"issue":"6 Pt 2","key":"659_CR11","doi-asserted-by":"publisher","first-page":"F1269","DOI":"10.1152\/ajprenal.1988.255.6.F1269","volume":"255","author":"BA Stanton","year":"1988","unstructured":"Stanton BA, Kaissling B. Adaptation of distal tubule and\n                        collecting duct to increased Na delivery. II. Na+ and K+ transport. Am J\n                        Physiol. 1988;255(6 Pt 2):F1269-75. https:\/\/doi.org\/10.1152\/ajprenal.1988.255.6.F1269.","journal-title":"Am J Physiol."},{"key":"659_CR12","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1056\/NEJMra1703100","volume":"377","author":"DH Ellison","year":"2017","unstructured":"Ellison DH, Felker GM. Diuretic treatment in heart failure. N\n                        Engl J Med. 2017;377:1964\u201375. https:\/\/doi.org\/10.1056\/NEJMra1703100.","journal-title":"N Engl J Med"},{"key":"659_CR13","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1681\/ASN.2016111178","volume":"28","author":"VS Rao","year":"2017","unstructured":"Rao VS, Planavsky N, Hanberg JS, Ahmad T, Brisco-Bacik MA,\n                        Wilson FP, et al. Compensatory distal reabsorption drives diuretic\n                        resistance in human heart failure. J Am Soc Nephrol. 2017;28:3414\u201324. https:\/\/doi.org\/10.1681\/ASN.2016111178.","journal-title":"J Am Soc Nephrol"},{"key":"659_CR14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/ejhf.2852","volume":"25","author":"J Biegus","year":"2023","unstructured":"\u2022 Biegus J, Zymli\u0144ski R, Testani J, Fudim M, Cox ZL, Guzik M,\n                        et al. The blunted loop diuretic response in acute heart failure is driven\n                        by reduced tubular responsiveness rather than insufficient tubular delivery.\n                        The role of furosemide urine excretion on diuretic and natriuretic response\n                        in acute heart failure. Eur J Heart Fail. 2023;25:1323\u201333. https:\/\/doi.org\/10.1002\/ejhf.2852. Patients with acute heart failure\n                            na\u00efve to loop diuretics had more robust diuretic response compared to\n                            chronic furosemide users. The greater diuretic response in loop diuretic\n                            na\u00efve patients was not due to better loop diuretic delivery to the\n                            nephron and it was related to a better tubular response to furosemide.\n                            This mechanistic study shows that in patients with acute heart failure,\n                            the blunted diuretic response is driven mainly by decreased tubular\n                            responsiveness rather than insufficient furosemide tubular\n                            delivery.","journal-title":"Eur J Heart Fail"},{"key":"659_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejim.2013.08.711","volume":"25","author":"JP Ferreira","year":"2014","unstructured":"Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P,\n                        Carvalho H. Mineralocorticoid receptor antagonism in acutely decompensated\n                        chronic heart failure. Eur J Intern Med. 2014;25:67\u201372. https:\/\/doi.org\/10.1016\/j.ejim.2013.08.711.","journal-title":"Eur J Intern Med"},{"key":"659_CR16","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","volume":"2","author":"J Butler","year":"2017","unstructured":"Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP,\n                        Konstam MA, et al. Efficacy and safety of spironolactone in acute heart\n                        failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol.\n                        2017;2:950\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2017.2198.\u00e7.","journal-title":"JAMA Cardiol"},{"key":"659_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/CRD.0b013e31822b4939","volume":"19","author":"R Kassamali","year":"2011","unstructured":"Kassamali R, Sica DA. Acetazolamide: a forgotten diuretic\n                        agent. Cardiol Rev. 2011;19:276\u20138. https:\/\/doi.org\/10.1097\/CRD.0b013e31822b4939.","journal-title":"Cardiol Rev"},{"key":"659_CR18","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","volume":"387","author":"W Mullens","year":"2022","unstructured":"\u2022\u2022 Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers\n                        E, et al. Acetazolamide in acute decompensated heart failure with volume\n                        overload. N Engl J Med. 2022;387:1185\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2203094. In patients with acute decompensated\n                            heart failure, and clinical signs of volume overload, the addition of\n                            500 mg of IV acetazolamide to standard loop diuretic therapy resulted in\n                            more diuresis, more natriuresis, shorter hospital stay, and an increased\n                            likelihood of being discharged without residual signs of volume\n                            overload. The results of this trial provide strong evidence to support\n                            the use of IV acetazolamide to achieve decongestion among patients with\n                            decompensated heart failure.","journal-title":"N Engl J Med"},{"key":"659_CR19","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1093\/eurheartj\/ehad557","volume":"44","author":"E Meekers","year":"2023","unstructured":"Meekers E, Dauw J, Martens P, Dhont S, Verbrugge FH, Nijst P,\n                        et al. Renal function and decongestion with acetazolamide in acute\n                        decompensated heart failure: the ADVOR trial. Eur Heart J. 2023;44:3672\u201382. https:\/\/doi.org\/10.1093\/eurheartj\/ehad557.","journal-title":"Eur Heart J"},{"key":"659_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1161\/CIRCULATIONAHA.122.062486","volume":"147","author":"P Martens","year":"2023","unstructured":"Martens P, Dauw J, Verbrugge FH, Nijst P, Meekers E, Augusto SN\n                        Jr, et al. Decongestion with acetazolamide in acute decompensated heart\n                        failure across the spectrum of left ventricular ejection fraction: a\n                        prespecified analysis from the ADVOR trial. Circulation. 2023;147:201\u201311. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062486.","journal-title":"Circulation"},{"key":"659_CR21","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/eurheartj\/ehad236","volume":"44","author":"P Martens","year":"2023","unstructured":"Martens P, Verbrugge FH, Dauw J, Nijst P, Meekers E, Augusto\n                        SN, et al. Pre-treatment bicarbonate levels and decongestion by\n                        acetazolamide: the ADVOR trial. Eur Heart J. 2023;44:1995\u20132005. https:\/\/doi.org\/10.1093\/eurheartj\/ehad236.","journal-title":"Eur Heart J"},{"key":"659_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.rec.2022.07.009","volume":"76","author":"R de la Espriella","year":"2023","unstructured":"de la Espriella R, Cobo M, Santas E, Verbrugge FH, Fudim M,\n                        Girerd N, Mi\u00f1ana G, G\u00f3rriz JL, Bay\u00e9s-Gen\u00eds A, N\u00fa\u00f1ez J. Assessment of filling\n                        pressures and fluid overload in heart failure: an updated perspective. Rev\n                        Esp Cardiol (Engl Ed). 2023;76:47\u201357. https:\/\/doi.org\/10.1016\/j.rec.2022.07.009.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"659_CR23","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2010.06.034","volume":"56","author":"JC Jentzer","year":"2010","unstructured":"Jentzer JC, DeWald TA, Hernandez AF. Combination of loop\n                        diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol.\n                        2010;56:1527\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2010.06.034.","journal-title":"J Am Coll Cardiol"},{"key":"659_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1136\/hrt.71.2.146","volume":"71","author":"KS Channer","year":"1994","unstructured":"Channer KS, McLean KA, Lawson-Matthew P, Richardson M.\n                        Combination diuretic treatment in severe heart failure: a randomised\n                        controlled trial. Br Heart J. 1994;71:146\u201350. https:\/\/doi.org\/10.1136\/hrt.71.2.146.","journal-title":"Br Heart J"},{"key":"659_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","volume":"44","author":"JC Trull\u00e0s","year":"2023","unstructured":"\u2022\u2022 Trull\u00e0s JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M,\n                        S\u00e1nchez-Marteles M, Conde-Martel A, et al. Combining loop with thiazide\n                        diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J.\n                        2023;44:411\u201321. https:\/\/doi.org\/10.1093\/eurheartj\/ehac689. This trial demonstrates the efficacy\n                            of the combination of loop and thiazide diuretics in patients with acute\n                            heart failure, who are already on moderate- to high-dose oral loop\n                            diuretic therapy (80\u2013240 mg furosemide\/day). The CLOROTIC is a welcome\n                            addition to a limited evidence base for combination diuretic management\n                            of AHF. It shows that HCTZ, an inexpensive thiazide diuretic, is a safe\n                            and modestly effective addition to loop diuretic therapy in patients\n                            with acute heart failure and volume\n                        overload.","journal-title":"Eur Heart J"},{"key":"659_CR26","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1002\/ejhf.2988","volume":"25","author":"JC Trull\u00e0s","year":"2023","unstructured":"Trull\u00e0s JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M,\n                        S\u00e1nchez-Marteles M, Conde-Martel A, et al. Combining loop and thiazide\n                        diuretics for acute heart failure across the estimated glomerular filtration\n                        rate spectrum: a post-hoc analysis of the CLOROTIC trial. Eur J Heart Fail.\n                        2023;25:1784\u201393. https:\/\/doi.org\/10.1002\/ejhf.2988.","journal-title":"Eur J Heart Fail"},{"key":"659_CR27","doi-asserted-by":"crossref","unstructured":"- S\u00e1nchez-Marteles M, Garc\u00e9s-Horna V, Morales-Rull JL, Casado\n                        J, Carrera-Izquierdo M, Conde-Martel A, et al. Combining loop and thiazide\n                        diuretics across the left-ventricle ejection fraction spectrum: the CLOROTIC\n                        trial. JACC Heart Fail. 2024 (in press)","DOI":"10.1016\/j.jchf.2024.05.006"},{"issue":"24","key":"659_CR28","doi-asserted-by":"publisher","first-page":"00003","DOI":"10.1016\/j.rceng.2023.11.003","volume":"S2254\u20138874","author":"A Conde-Martel","year":"2024","unstructured":"Conde-Martel A, Trull\u00e0s JC, Morales-Rull JL, Casado J,\n                        Carrera-Izquierdo M, S\u00e1nchez-Marteles M, et al. Sex differences in clinical\n                        characteristics and outcomes in the CLOROTIC (combining loop with thiazide\n                        diuretics for decompensated heart failure) trial. Rev Clin Esp (Barc).\n                        2024;S2254\u20138874(24):00003\u201311. https:\/\/doi.org\/10.1016\/j.rceng.2023.11.003.","journal-title":"Rev Clin Esp (Barc)"},{"key":"659_CR29","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/ejhf.1713","volume":"22","author":"K Damman","year":"2020","unstructured":"Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan\n                        A, et al. Randomized, double-blind, placebo-controlled, multicentre pilot\n                        study on the effects of empagliflozin on clinical outcomes in patients with\n                        acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail.\n                        2020;22:713\u201322. https:\/\/doi.org\/10.1002\/ejhf.1713.","journal-title":"Eur J Heart Fail"},{"key":"659_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","volume":"146","author":"PC Schulze","year":"2022","unstructured":"Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F,\n                        Grund S, et al. Effects of early empagliflozin initiation on diuresis and\n                        kidney function in patients with acute decompensated heart failure\n                        (EMPAG-HF). Circulation. 2022;146:289\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059038.","journal-title":"Circulation"},{"key":"659_CR31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M,\n                        Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized\n                        for acute heart failure: a multinational randomized trial. Nat Med.\n                        2022;28:568\u201374. https:\/\/doi.org\/10.1038\/s41591-021-01659-1.","journal-title":"Nat Med"},{"key":"659_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","volume":"44","author":"J Biegus","year":"2023","unstructured":"\u2022\u2022 Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR,\n                        Angermann CE, et al. Impact of empagliflozin on decongestion in acute heart\n                        failure: the EMPULSE trial. Eur Heart J. 2023;44:41\u201350. https:\/\/doi.org\/10.1093\/eurheartj\/ehac530. This pre-specified subanalysis of\n                            decongestion-related endpoints of the EMPULSE trial showed that the\n                            initiation of empagliflozin in acute heart failure patients after\n                            initial in-hospital stabilization resulted in an early, effective, and\n                            sustained improvements in all decongestion indexes, which was associated\n                            with clinical benefit at day 90.","journal-title":"Eur Heart J"},{"key":"659_CR33","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","volume":"83","author":"ZL Cox","year":"2024","unstructured":"Cox ZL, Collins SP, Hernandez GA, McRae AT 3rd, Davidson BT,\n                        Adams K, et al. Efficacy and Safety of Dapagliflozin in Patients With Acute\n                        Heart Failure. J Am Coll Cardiol. 2024;83:1295\u2013306. https:\/\/doi.org\/10.1016\/j.jacc.2024.02.009.","journal-title":"J Am Coll Cardiol"},{"key":"659_CR34","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1093\/eurheartj\/ehad341","volume":"44","author":"SE Yeoh","year":"2023","unstructured":"Yeoh SE, Osmanska J, Petrie MC, Brooksbank KJM, Clark AL,\n                        Docherty KF, et al. Dapagliflozin vs. metolazone in heart failure resistant\n                        to loop diuretics. Eur Heart J. 2023;44:2966\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehad341.","journal-title":"Eur Heart J"},{"key":"659_CR35","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni\n                        AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized\n                        for worsening heart failure: the EVEREST Outcome Trial. JAMA.\n                        2007;297:1319\u201331. https:\/\/doi.org\/10.1001\/jama.297.12.1319.","journal-title":"JAMA"},{"key":"659_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","volume":"22","author":"Y Matsue","year":"2016","unstructured":"Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, et\n                        al. Clinical effectiveness of tolvaptan in patients with acute heart failure\n                        and renal dysfunction. J Card Fail. 2016;22:423\u201332. https:\/\/doi.org\/10.1016\/j.cardfail.2016.02.007.","journal-title":"J Card Fail"},{"key":"659_CR37","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ehf2.12124","volume":"4","author":"A Pose","year":"2017","unstructured":"Pose A, Almenar L, Gavira JJ, L\u00f3pez-Granados A, Blasco T,\n                        Delgado J, et al. Benefit of tolvaptan in the management of hyponatraemia in\n                        patients with diuretic-refractory congestive heart failure: the SEMI-SEC\n                        project. ESC Heart Fail. 2017;4:130\u20137. https:\/\/doi.org\/10.1002\/ehf2.12124.","journal-title":"ESC Heart Fail"},{"key":"659_CR38","doi-asserted-by":"publisher","first-page":"783181","DOI":"10.3389\/fcvm.2021.783181","volume":"8","author":"NG Minh","year":"2022","unstructured":"Minh NG, Hoang HN, Maeda D, Matsue Y. Tolvaptan add-on therapy\n                        to overcome loop diuretic resistance in acute heart failure with renal\n                        dysfunction (DR-AHF): design and rationale. Front Cardiovasc Med.\n                        2022;8:783181. https:\/\/doi.org\/10.3389\/fcvm.2021.783181.","journal-title":"Front Cardiovasc Med"},{"key":"659_CR39","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1067\/mhj.2003.166","volume":"145","author":"G Licata","year":"2003","unstructured":"Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra\n                        A, Follone G, et al. Effects of high-dose furosemide and small-volume\n                        hypertonic saline solution infusion in comparison with a high dose of\n                        furosemide as bolus in refractory congestive heart failure: long-term\n                        effects. Am Heart J. 2003;145:459\u201366. https:\/\/doi.org\/10.1067\/mhj.2003.166.","journal-title":"Am Heart J"},{"key":"659_CR40","doi-asserted-by":"publisher","unstructured":"Retraction. Low sodium versus normal sodium diets in systolic\n                        heart failure: systematic review and meta-analysis. Heart. Published Online\n                        First: 21 August 2012 https:\/\/doi.org\/10.1136\/heartjnl-2012-302337. Heart. 2013;99(11):820. https:\/\/doi.org\/10.1136\/heartjnl-2011-301156.29ret.","DOI":"10.1136\/heartjnl-2012-302337 10.1136\/heartjnl-2011-301156.29ret"},{"key":"659_CR41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jchf.2019.10.012","volume":"8","author":"M Griffin","year":"2020","unstructured":"Griffin M, Soufer A, Goljo E, Colna M, Rao VS, Jeon S, et al.\n                        Real world use of hypertonic saline in refractory acute decompensated heart\n                        failure: a U.S. center\u2019s experience. JACC Heart Fail. 2020;8:199\u2013208. https:\/\/doi.org\/10.1016\/j.jchf.2019.10.012.","journal-title":"JACC Heart Fail"},{"key":"659_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14720","author":"M Cobo Marcos","year":"2024","unstructured":"Cobo Marcos M, Com\u00edn-Colet J, de la Espriella R, Rubio Gracia\n                        J, Morales-Rull JL, Zegr\u00ed I, et al. Design and baseline characteristics of\n                        SALT-HF trial: hypertonic saline therapy in ambulatory heart failure. ESC\n                        Heart Fail. 2024Feb 21. https:\/\/doi.org\/10.1002\/ehf2.14720.","journal-title":"ESC Heart Fail"},{"key":"659_CR43","doi-asserted-by":"publisher","first-page":"750794","DOI":"10.1155\/2013\/750794","volume":"2013","author":"R Jermyn","year":"2013","unstructured":"Jermyn R, Rajper N, Estrada C, Patel S, Weisfelner Bloom M, et\n                        al. Triple diuretics and aquaretic strategy for acute decompensated heart\n                        failure due to volume overload. Case Rep Cardiol. 2013;2013:750794. https:\/\/doi.org\/10.1155\/2013\/750794.","journal-title":"Case Rep Cardiol"},{"key":"659_CR44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/IJNRD.S135660","volume":"10","author":"M Goyfman","year":"2017","unstructured":"Goyfman M, Zamudio P, Jang K, Chee J, Miranda C, Butler J, et\n                        al. Combined aquaretic and diuretic therapy in acute heart failure. Int J\n                        Nephrol Renovasc Dis. 2017;10:129\u201334. https:\/\/doi.org\/10.2147\/IJNRD.S135660.","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"659_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cardfail.2021.07.016","volume":"28","author":"ZL Cox","year":"2022","unstructured":"Cox ZL, Sarrell BA, Cella MK, Tucker B, Arroyo JP, Umanath K,\n                        et al. Multinephron segment diuretic therapy to overcome diuretic resistance\n                        in acute heart failure: a single-center experience. J Card Fail.\n                        2022;28:21\u201331. https:\/\/doi.org\/10.1016\/j.cardfail.2021.07.016.","journal-title":"J Card Fail"},{"key":"659_CR46","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1001\/jama.2022.23924","volume":"329","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Anstrom KJ, Eisenstein EL, Sapp S, Greene SJ, Morgan\n                        S, et al. Effect of torsemide vs furosemide after discharge on all-cause\n                        mortality in patients hospitalized with heart failure: the TRANSFORM-HF\n                        randomized clinical trial. JAMA. 2023;329:214\u201323. https:\/\/doi.org\/10.1001\/jama.2022.23924.","journal-title":"JAMA"},{"key":"659_CR47","unstructured":"Mir\u00f3 O, N\u00fa\u00f1ez J, Trull\u00e0s JC, Lopez-Ayala P, Llauger L,\n                        Alqu\u00e9zar-Arb\u00e9 A, et al. Combining loop with thiazide diuretics in patients\n                        discharged home after a heart failure decompensation: effect on 30-day\n                        outcomes. Eur J Intern Med. 2024 (in press)"},{"key":"659_CR48","unstructured":"The Heart Failure Diuresis Efficacy Comparison (DEA-HF) Study.\n                        ClinicalTrials.gov ID NCT05904808. Available at ClinicalTrials.gov.\n                            https:\/\/clinicaltrials.gov\/study\/NCT05904808"},{"key":"659_CR49","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1005419","volume":"364","author":"GM Felker","year":"2011","unstructured":"Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW,\n                        Goldsmith SR, et al. Diuretic strategies in patients with acute\n                        decompensated heart failure. N Engl J Med. 2011;364:797\u2013805. https:\/\/doi.org\/10.1056\/NEJMoa1005419.","journal-title":"N Engl J Med"},{"key":"659_CR50","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/ejhf.2664","volume":"24","author":"J N\u00fa\u00f1ez","year":"2022","unstructured":"N\u00fa\u00f1ez J, de la Espriella R, Rossignol P, Voors AA, Mullens W,\n                        Metra M, et al. Congestion in heart failure: a circulating biomarker-based\n                        perspective. A review from the Biomarkers Working Group of the Heart Failure\n                        Association, European Society of Cardiology. Eur J Heart Fail.\n                        2022;24:1751\u201366. https:\/\/doi.org\/10.1002\/ejhf.2664.","journal-title":"Eur J Heart Fail"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-024-00659-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-024-00659-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-024-00659-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T14:19:36Z","timestamp":1724077176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-024-00659-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["659"],"URL":"https:\/\/doi.org\/10.1007\/s11897-024-00659-9","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"assertion":[{"value":"20 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JC received consulting and lecture fees from AstraZeneca,\n                    Boehringer Ingelheim, Novartis and Vifor Pharma (outside the submitted work).\n                    MCM reports personal fees or advisory boards from AstraZeneca, Boehringer\n                    Ingelheim, Bayer, Novartis, NovoNordisk, Rovi, and Vifor Pharma (outside the\n                    submitted work). JLMR received consulting and lecture fees from AstraZeneca,\n                    Boehringer Ingelheim, Esteve and Zambon. JN reports personal fees or advisory\n                    boards from Alleviant, AstraZeneca, Boehringer Ingelheim, Bayer, Novartis,\n                    NovoNordisk, Pfizer, Rovi, and Vifor Pharma (outside the submitted work). LM\n                    reports personal fees or advisory boards from AstraZeneca, Boehringer Ingelheim,\n                    Lilly, Bayer, Novartis and Rovi (outside the submitted work). JCT and FF declare\n                    that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal\n                    subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}